Agrawal, A http://orcid.org/0000-0002-0313-793X
Chou, Y-L
Carey, C E
Baranger, D A A
Zhang, B
Sherva, R
Wetherill, L
Kapoor, M
Wang, J-C
Bertelsen, S
Anokhin, A P
Hesselbrock, V
Kramer, J
Lynskey, M T
Meyers, J L
Nurnberger, J I
Rice, J P
Tischfield, J
Bierut, L J
Degenhardt, L
Farrer, L A
Gelernter, J http://orcid.org/0000-0002-4067-1859
Hariri, A R
Heath, A C
Kranzler, H R
Madden, P A F
Martin, N G
Montgomery, G W
Porjesz, B
Wang, T http://orcid.org/0000-0002-6800-242X
Whitfield, J B
Edenberg, H J
Foroud, T
Goate, A M
Bogdan, R
Nelson, E C
Article History
Received: 10 October 2016
Revised: 26 June 2017
Accepted: 13 July 2017
First Online: 7 November 2017
Competing interests
: We disclose that Drs LJ Bierut, JP Rice, J-C Wang and AM Goate are listed as inventors on the patent ‘Markers for Addiction’ (US 20070258898) covering the use of certain SNPs in determining the diagnosis, prognosis and treatment of addiction. Dr Kranzler has been a consultant, advisory board member or CME speaker for Lundbeck, and Indivior. He is also a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative (ACTIVE), which was supported in the last three years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor and Amygdala Neurosciences. Dr Nurnberger is an investigator for Assurex and a consultant for Janssen. All other authors declare no conflicts of interest.